Eli Lilly’s existing 2024 material transfer agreement with Peptron keeps joint research on SmartDepot sustained-release microsphere technology in the feasibility and evaluation phase rather than advancing to a commercial license. Recent July 2026 updates from Peptron confirm the collaboration covers multiple peptide candidates and remains on track, yet explicitly separate it from Mounjaro or Zepbound applications, while Lilly has already executed a technology licensing deal with Camurus for comparable long-acting delivery. With only weeks remaining until the October 7 resolution date and no public announcements or filings indicating imminent commercial terms, trader consensus heavily favors no deal, reflecting the typical multi-month timeline required to negotiate, due-diligence, and finalize such agreements in the biopharma sector.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড16% সম্ভাবনা
$11,264 Vol.
$11,264 Vol.
Oct 6, 2026
16% সম্ভাবনা
$11,264 Vol.
$11,264 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing 2024 material transfer agreement with Peptron keeps joint research on SmartDepot sustained-release microsphere technology in the feasibility and evaluation phase rather than advancing to a commercial license. Recent July 2026 updates from Peptron confirm the collaboration covers multiple peptide candidates and remains on track, yet explicitly separate it from Mounjaro or Zepbound applications, while Lilly has already executed a technology licensing deal with Camurus for comparable long-acting delivery. With only weeks remaining until the October 7 resolution date and no public announcements or filings indicating imminent commercial terms, trader consensus heavily favors no deal, reflecting the typical multi-month timeline required to negotiate, due-diligence, and finalize such agreements in the biopharma sector.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 5, 2026, 8:02 PM ET
ভলিউম
$11,264শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing 2024 material transfer agreement with Peptron keeps joint research on SmartDepot sustained-release microsphere technology in the feasibility and evaluation phase rather than advancing to a commercial license. Recent July 2026 updates from Peptron confirm the collaboration covers multiple peptide candidates and remains on track, yet explicitly separate it from Mounjaro or Zepbound applications, while Lilly has already executed a technology licensing deal with Camurus for comparable long-acting delivery. With only weeks remaining until the October 7 resolution date and no public announcements or filings indicating imminent commercial terms, trader consensus heavily favors no deal, reflecting the typical multi-month timeline required to negotiate, due-diligence, and finalize such agreements in the biopharma sector.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ভলিউম
$11,264শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing 2024 material transfer agreement with Peptron keeps joint research on SmartDepot sustained-release microsphere technology in the feasibility and evaluation phase rather than advancing to a commercial license. Recent July 2026 updates from Peptron confirm the collaboration covers multiple peptide candidates and remains on track, yet explicitly separate it from Mounjaro or Zepbound applications, while Lilly has already executed a technology licensing deal with Camurus for comparable long-acting delivery. With only weeks remaining until the October 7 resolution date and no public announcements or filings indicating imminent commercial terms, trader consensus heavily favors no deal, reflecting the typical multi-month timeline required to negotiate, due-diligence, and finalize such agreements in the biopharma sector.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা